细环病毒
肾移植
病毒载量
医学
移植
内科学
病毒血症
病毒
免疫学
胃肠病学
聚合酶链反应
生物
生物化学
基因
作者
Irene Görzer,Frederik Haupenthal,Fabrizio Maggi,Fanny Gelas,Dorian Kulifaj,Ludovic Brossault,Elisabeth Puchhammer‐Stöckl,Gregor Bond
标识
DOI:10.1016/j.jcv.2022.105348
摘要
Torque Teno virus (TTV) is non-pathogenic, highly prevalent and reflects the immune status of its host. TTV plasma load was suggested for risk stratification of graft rejection and infection post kidney-transplantation, for which most studies applied an in-house PCR. Recently, a commercial PCR was CE-certified for clinical use. The present study was designed to assess the performance of TTV load as quantified by the commercial PCR in the prediction of graft rejection and infection.Patients and events were selected from the prospective TTV-POET trial, including 683 consecutive adult recipients of a kidney-graft transplanted at the Medical University Vienna, 2016-2020. TTV was quantified in plasma drawn in Months 4-12 post-transplant by in-house and commercial PCR and associated with consecutive infections and graft rejections until Month 12 post-transplantation.A total of 342 samples from 314 patients with 85 biopsies (rejection, n = 18) and 79 infectious events were assessed. The two PCRs were highly associated (estimate 0.91, 95%CI 0.89-0.93), with a mean difference of 1.38 log10 copies/mL (95%CI 1.46-1.30). The risk of rejection decreased by 25% with every log10 increase in TTV load as quantified by commercial PCR (RR 0.75, 95%CI 0.67-0.85), and the risk of infection increased by 6% (RR 1.06, 95%CI 1.00-1.12).These data support the value of TTV quantification by commercial PCR for the risk stratification of graft rejection and infection in the first year post kidney-transplantation. The test performance determined within this study may serve to design clinical trials and subsequently, support application in clinical routine.
科研通智能强力驱动
Strongly Powered by AbleSci AI